Authors' reply

BMJ 1996; 312 doi: https://doi.org/10.1136/bmj.312.7034.847 (Published 30 March 1996) Cite this as: BMJ 1996;312:847
  1. R Madhok,
  2. N Maiden
  1. Consultant rheumatologist Senior house officer Royal Infirmary, Glasgow G4 0SF

    EDITOR,—M J Shield and S V Morant agree with us about the usefulness of deriving values for the number of patients needed to be treated with misoprostol to prevent serious upper gastrointestinal complications associated with non-steroidal anti-inflammatory drugs. We disagree, however, with their criticism of our exclusion of gastrointestinal haemorrhage from the number needed to treat analysis in …

    View Full Text

    Sign in

    Log in through your institution